Chem. Soc. Rev., 2014, 43(9), 2904-2915
Fernando López (A Estrada, 1975) obtained his PhD in 2003 at the University of Santiago de Compostela.
He carried out two predoctoral stays at the ETH-Zürich (with Prof. Erick M. Carreira) and at Yale University (with Prof. John F. Hartwig), and a postdoctoral stay with Prof. Ben L. Feringa at the University of Groningen (Marie Curie Fellow, from 2004 to 2006).
In 2006, he joined the University of Santiago de Compostela as a Ramón y Cajal Fellow and, in 2008, he was granted a Tenured Scientist position at the Spanish National Research Council (CSIC), joining the Instituto de Química Orgánica General (IQOG).
In 2009, he received the RSEQ-SIGMA-ALDRICH Young Chemists Award.
Since 2012, he has been temporarily assigned at the Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), at the University of Santiago de Compostela.
He is the author of more than 60 publications and 2 patents.
h = 29, > 2400 citations
We are interested in the development of cost-effective, innovative and creative catalytic synthetic methods that allow a straightforward and versatile entry to a variety of target-relevant molecular frameworks from very simple, readily accessible substances. Moreover, a key feature of the research consists on the development of enantioselective versions of these synthetic methods,by designing and/or using novel chiral catalysts.
Whitin this context, in collaboration wit Prof J. L. Mascareñas at CIQUS, we are particularly interested in the development of:
Many structurally complex natural products with very promising biological activities can only be obtained from nature in low amounts, completely insufficient to carry out all the required biological and medicinal studies. Moreover, since their structures are very complex, their synthesis in multigram scales, as well as the access to potentially more active analogues, is very often inefficient (more than 30 synthetic steps, low yields and/or selectivities). Among these products, we are interested in promising cytotoxic agents: guaianes like Englerin A (renal cancer), Arglabin (lung cancer), tiglianes like Sapinsignoids (lung cancer) or some marine products like Bielschowskysin (renal and lung cancer).
Our aim, taking advantage of the above mentioned methodology program, is to apply the newly developed synthetic methods to provide a highly efficient, versatile and enantio selective entry to some of these structurally complex polycyclic products as well as to more active analogues The design and synthesis of structurally related probes which could be used to shed light on their biological functions of this targets is also a key objective.
Having access to these structurally complex natural products and related analogues, we collaborate
with (chemical) biologists to advance in the knowledge of their biological roles, including the identification
of their cellular targets and the study of their molecular mechanism of action.
New research interests, in collaboration with Prof. J. L. Mascareñas and Prof. M. A Correa (U. de Vigo) involve the development of novel hetereogenized transition metal catalysts (nanoreactors), as well as the invention of new transition metal catalyzed reactions that can be performed in water and even in biological environments.
Beilstein J. Org. Chem, 2013, 9, 2250-2264
Chem. Eur. J., 2013, 19(30), 15248-15260
Organometallics, 2013, 32 (17), 4851–4861
Angew. Chem. Int. Ed., 2013, 52, 6526-6530
Org. Lett, 2012, 14, 2996-2999
J. Am. Chem. Soc., 2012, 134, 14322–14325
Adv. Synth. Catal., 2012, 354 (9), 1658-1664
Chem. Eur. J., 2011, 17, 418-428
J. Am. Chem. Soc., 2011, 133, 7660-7663
Dalton Trans., 2011, 40, 11095-11105
Beilstein J. Org. Chem, 2011, 7, 1075-1094
Angew. Chem. Int. Ed., 2011, 50, 11496-11500
Chem. Sci., 2011, 2, 633-637
Angew. Chem. Int. Ed., 2010, 49, 9886-9890
Anales de Química, 2010, 106, 191-198
Chem. Commun, 2010, 46, 270–272
J. Am. Chem. Soc., 2010, 132, 454–455